Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction.

[1]  S. Tyagi,et al.  Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts , 1996, Molecular and Cellular Biochemistry.

[2]  A. Wear.  CIRCULATION , 1964, The Lancet.

[3]  J. Dyck,et al.  Intracellular Action of Matrix Metalloproteinase-2 Accounts for Acute Myocardial Ischemia and Reperfusion Injury , 2002, Circulation.

[4]  R. Schulz,et al.  Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. , 2002, Cardiovascular research.

[5]  A. Ghahary,et al.  Healing of burn wounds in transgenic mice overexpressing transforming growth factor-beta 1 in the epidermis. , 2001, The American journal of pathology.

[6]  Y. Miyamoto,et al.  Activation of Matrix Metalloproteinases by Peroxynitrite-induced Protein S-Glutathiolation via Disulfide S-Oxide Formation* , 2001, The Journal of Biological Chemistry.

[7]  C. Overall,et al.  Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. , 2001, Cancer research.

[8]  J. D’Armiento,et al.  Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. , 2000, The Journal of clinical investigation.

[9]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[10]  P. Ferdinandy,et al.  Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. , 2000, Circulation research.

[11]  P. Libby,et al.  Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. , 2000, The Journal of clinical investigation.

[12]  M. Radomski,et al.  Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. , 2000, Circulation.

[13]  A. Delcourt,et al.  Altered balance between matrix gelatinases (MMP‐2 and MMP‐9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP‐9 in myosin‐heavy chain degradation , 1999, European journal of heart failure.

[14]  M. Radomski,et al.  Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. , 1999, Circulation research.

[15]  M. Zile,et al.  Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. , 1999, The Journal of pharmacology and experimental therapeutics.

[16]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[17]  M. Zile,et al.  Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. , 1999, Circulation research.

[18]  P. Libby,et al.  Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. , 1999, Circulation.

[19]  P. Ferdinandy,et al.  Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. , 1999, The American journal of physiology.

[20]  Y. Sun,et al.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.

[21]  A. Wechsler,et al.  Decreased expression of tissue inhibitor of metalloproteinase 1 in stunned myocardium. , 1998, The Journal of surgical research.

[22]  F. Spinale,et al.  Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .

[23]  Y. Okada,et al.  Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. , 1998, Journal of medicinal chemistry.

[24]  F. Spinale,et al.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. , 1998, Circulation research.

[25]  M. Radomski,et al.  Release of gelatinase A during platelet activation mediates aggregation , 1997, Nature.

[26]  R. Schulz,et al.  Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. , 1997, Cardiovascular research.

[27]  R. Khokha,et al.  Murine tissue inhibitor of metalloproteinases—4 (Timp—4): cDNA isolation and expression in adult mouse tissues 1 , 1997, FEBS letters.

[28]  D. Harrison,et al.  Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. , 1996, The Journal of clinical investigation.

[29]  J. Greene,et al.  Molecular Cloning and Characterization of Human Tissue Inhibitor of Metalloproteinase 4* , 1996, The Journal of Biological Chemistry.

[30]  J. Zweier,et al.  Measurement of Nitric Oxide and Peroxynitrite Generation in the Postischemic Heart , 1996, The Journal of Biological Chemistry.

[31]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[32]  D. Blake,et al.  Inactivation of tissue inhibitor of metalloproteinase‐1 by peroxynitrite , 1996, FEBS letters.

[33]  E. Lonn,et al.  Effects of oxygen free radicals and scavengers on the cardiac extracellular collagen matrix during ischemia-reperfusion. , 1994, The Canadian journal of cardiology.

[34]  H. Birkedal‐Hansen,et al.  The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Freeman,et al.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Garcia-Dorado,et al.  Cardiovascular Research , 1966 .